PeptidePeptideGLP-1 receptor agonistBiased agonist
Ecnoglutide
Also known as XW003
Investigational cAMP-biased GLP-1 receptor agonist in clinical development for obesity and type 2 diabetes, mainly in China. Early/mid-stage human data show dose-dependent weight loss.
01 Overview
Ecnoglutide (XW003) is a long-acting GLP-1 receptor agonist engineered to be biased toward cAMP signalling, intended to maximise metabolic efficacy. It is being developed by Sciwind Biosciences with once-weekly subcutaneous dosing.
Phase 2 trials in China have reported meaningful, dose-dependent weight loss and HbA1c reduction. The evidence base is still early relative to approved agents, and long-term safety data are limited.
02 Mechanism
Selectively agonises the GLP-1 receptor with cAMP-biased signalling, enhancing insulin secretion and appetite suppression.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Trial dose | 1.2–2.4 mg/wk | SubQ | Doses evaluated in Phase 2 obesity studies |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Weight lossDose-dependent reduction in Phase 2 obesity trials. | ~10-15% at higher doses | Clinical | |
| Improved glycaemic controlReduced HbA1c in type 2 diabetes cohorts. | HbA1c reduction | Clinical |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Nausea and GI effectsTypical GLP-1 class GI effects during titration. | Moderate | Very common | Clinical | |
| Decreased appetiteExpected appetite suppression; can cause under-eating. | Mild | Very common | Clinical |
06 Legal status
United States
Investigational
Not approved · as of Jan 2026
CN
Investigational
In clinical development · as of Jan 2026
07 References
Ecnoglutide (XW003) in overweight/obesity: a phase 2 trialSciwind Phase 2, 2024
08 Discussion0 comments
Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.
This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.